Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
Overview
Applied DNA Sciences is a biotechnology company specializing in the enzymatic production and detection of synthetic deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) using advanced polymerase chain reaction (PCR) technologies. The company caters to multiple industries with a focus on nucleic acid-based therapeutics, molecular diagnostics, and forensic authentication to secure supply chains and protect intellectual property.
Core Business Segments
- Therapeutic DNA Production Services: Leveraging its proprietary Linea DNA platform, the company produces highly pure, scalable synthetic DNA that serves as a critical component in the manufacture of nucleic acid-based therapies, including mRNA therapeutics and DNA vaccines.
- MDx Testing Services: Through its molecular diagnostics (MDx) capabilities, Applied DNA Sciences performs advanced genetic and clinical laboratory testing. These services are directed at ensuring accurate diagnostic results and personalized treatment strategies, contributing to better patient outcomes.
- DNA Tagging and Security Products & Services: With innovative solutions like the CertainT platform, the company provides botanical-DNA based security and authentication technology. This system verifies the authenticity of materials in supply chains, thereby protecting brands, assets, and intellectual property from fraud, counterfeiting, and diversion.
Key Technologies and Platforms
Applied DNA Sciences stands out due to its integration of state-of-the-art biochemical processes and robust forensic methodologies. Its proprietary platforms include:
- Linea DNA: A cell-free, enzymatic production platform that generates high-fidelity synthetic DNA constructs with versatile applications in therapeutics and diagnostics.
- Linea IVT: This innovative platform pairs DNA IVT templates with a next-generation RNA polymerase, streamlining mRNA production while reducing double-stranded RNA contamination, a critical factor in ensuring product purity and regulatory compliance.
- CertainT: A comprehensive traceability solution that integrates isotopic testing, DNA tagging, and genomic analyses. This platform delivers multiple key proof points to verify the origin and authenticity of raw materials and finished products, particularly within the textile industry.
Market Position and Strategic Significance
By combining advanced manufacturing protocols with forensic traceability techniques, Applied DNA Sciences provides robust solutions that address critical challenges across various sectors. The company's technologies not only enhance the efficiency of nucleic acid-based therapeutics production but also fortify supply chains against counterfeiting and fraud. Its unique approach of integrating multiple layers of verification underlines its commitment to quality, security, and innovation.
Operational Excellence and Industry Impact
The firm's reliance on enzymatic PCR-based processes sets it apart as an expert in producing synthetic DNA with high scalability and fidelity. This technical proficiency supports a diverse customer base, including pharmaceutical developers, diagnostic laboratories, governmental agencies, and global manufacturers who demand reliable, secure, and innovative solutions. Furthermore, by continuously refining its production and testing methodologies, the company demonstrates a strong dedication to research and development, ensuring its processes remain at the forefront of biotechnology innovation.
Conclusion
Overall, Applied DNA Sciences delivers comprehensive solutions that span from the production of synthetic DNA for advanced therapeutics to the forensic authentication of products in global supply chains. Its balanced focus on clinical, industrial, and security applications positions the company as a multifaceted player in the biotechnology sector, dedicated to enhancing product integrity and operational efficiency through innovative, proof-based technologies.
News
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) will release its first quarter fiscal 2024 financial results on February 8, 2024, after market close. A conference call for analysts and investors will be held the same day at 4:30 p.m. ET to discuss the financial results and recent accomplishments. The call will be accessible via dial-in and live webcast, with a replay available for 7 days. An accompanying slide presentation will be available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) has closed a direct offering of common stock and issued unregistered warrants to certain institutional investors. The company also amended the exercise price and expiration dates of previously issued common stock warrants. The net proceeds from the offering will be used for therapeutic DNA production services and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) has entered into securities purchase agreements with existing institutional investors for the issuance and sale of 5,644,061 shares of common stock at a purchase price of $0.609 per share in a registered direct offering. In a concurrent private placement, the company has also agreed to issue and sell unregistered warrants to purchase up to 11,288,122 shares of its common stock. The warrants have an exercise price of $0.609 per share and will become exercisable on the first trading day after receipt of shareholder approval. Additionally, the company will reduce the exercise price of 3,055,139 common stock warrants previously issued to the investors and extend warrant expiration dates into 2028, subject to approval by the company's stockholders at a stockholder meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) and Kudo Biotechnology (Kudo Bio) have entered into a joint development agreement to integrate Applied DNA's Linea IVT platform into Kudo Bio's commercial mRNA manufacturing workflows. The agreement aims to optimize mRNA quality, yields, and mitigate contamination by double-stranded RNA (dsRNA) at manufacturing scale. Upon successful completion, the joint workflow is planned for commercial launch in the second half of calendar 2024. The Linea IVT Platform is expected to provide advantages over conventional mRNA manufacturing methods, including the prevention or reduction of dsRNA contamination and reduced mRNA manufacturing turn-around-times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
-
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) announced consolidated financial results for its fourth quarter ended September 30, 2023. The company's total revenues were approximately $780 thousand, a decrease from $3.6 million for the same period in the prior fiscal year. Operating loss decreased to $4.2 million for the three-month period ended September 30, 2023, as compared to $4.3 million for the fourth quarter of fiscal 2022. Net loss was $3.6 million for the three-month period ended September 30, 2023, compared to $665 thousand for the fourth quarter of 2022. Cash and cash equivalents stood at $7.2 million on September 30, 2023, compared with $10.8 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.52%
Tags
-
News
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) will release its Q4 and full year 2023 financial results on December 7, 2023, after the market close. The company will host a conference call to discuss the results and answer questions at 4:30 p.m. ET. Details for accessing the call and webcast are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
News
Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) announced a follow-on order for Linea DNA valued above the mid-six figures for a global manufacturer of in vitro diagnostics. Deliveries are expected to commence from March 31, 2024, through December 31, 2024. Dr. James A. Hayward, president and CEO, highlighted the strong demand for IVD-related applications for Linea DNA, emphasizing the potential for high-margin recurring revenues and incremental revenues through new customer acquisition and expanded use by existing customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
-
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) announced the expansion of its Linea™ IVT platform to include the manufacture of self-amplifying mRNA (saRNA). The Platform was previously optimized for conventional non-amplifying mRNA constructs and has now been extended to enable the production of saRNA, a promising new form of mRNA therapy engineered to possess self-replicating capability. This expansion increases the Company's total addressable market and is the result of ongoing platform development and optimization. The Company believes that the Platform provides numerous advantages over conventional mRNA manufacturing methods, including higher target mRNA yields, faster delivery of IVT templates, and reduced manufacturing complexities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
-
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) announced the successful manufacturing and shipment of self-amplifying mRNA (saRNA) template using its Linea™ DNA platform to an unidentified preclinical therapeutic mRNA developer. This saRNA technology is gaining interest due to its self-replicating capability, resulting in a higher therapeutic index at a lower dose. The Company's Platform can efficiently produce the challenging DNA sequences necessary to manufacture saRNA at scale, positioning it at the forefront of template manufacturing for this promising mRNA modality.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
Rhea-AI Summary
Applied DNA Sciences and Cornell University College of Veterinary Medicine sign agreement to accelerate development of LineaDNA™-LNP-based veterinary vaccine platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
FAQ
What is the current stock price of Applied Dna Scie (APDN)?
The current stock price of Applied Dna Scie (APDN) is $1.18 as of April 10, 2025.
What is the market cap of Applied Dna Scie (APDN)?
The market cap of Applied Dna Scie (APDN) is approximately 1.3M.
What is the core business of Applied DNA Sciences?
Applied DNA Sciences is focused on the enzymatic production and detection of synthetic DNA and RNA. Its offerings span nucleic acid-based therapeutics, molecular diagnostics, and forensic supply chain security solutions.
How does the company ensure supply chain security?
The company utilizes its proprietary CertainT platform, which combines DNA tagging with isotopic and genomic testing to authenticate materials. This multi-proof approach helps verify origin and protect brands against counterfeiting and diversion.
What are the primary business segments of Applied DNA Sciences?
The company operates across three main segments: therapeutic DNA production services, MDx testing services in molecular diagnostics, and DNA tagging/security products for supply chain authentication.
What technologies support their manufacturing processes?
Applied DNA employs advanced PCR-based enzymatic processes. Its proprietary platforms, such as Linea DNA and Linea IVT, facilitate scalable and high-fidelity production of synthetic DNA and mRNA.
How does the Linea IVT platform enhance mRNA production?
The Linea IVT platform combines DNA IVT templates with a proprietary RNA polymerase, significantly reducing double-stranded RNA contamination and streamlining the mRNA manufacturing workflow.
Who are the typical customers of Applied DNA Sciences?
The company's customers include pharmaceutical and biotechnology firms, diagnostic laboratories, governmental agencies, and industrial manufacturers that require secure, high-quality nucleic acid solutions.
How does Applied DNA Sciences maintain quality and product integrity?
Through rigorous process development and the use of state-of-the-art enzymatic production technologies, the company ensures high fidelity and consistency in its synthetic DNA products, while forensic traceability measures further authenticate its outputs.
In what ways does Applied DNA contribute to innovation in biotechnology?
By integrating advanced PCR technology with forensic authentication and scalable production platforms, the company provides innovative solutions that address both clinical and industrial challenges, fostering greater efficiency and security in genetic medicine and supply chain management.
Applied Dna Scie
Nasdaq:APDN
APDN Rankings
APDN Stock Data
1.30M
888.82k
19.47%
26.9%
5.44%
Diagnostics & Research
Services-testing Laboratories
United States
STONY BROOK